☰

Sushrusha Nayak, Ph.D. - Publications

Affiliations: 
2010 University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Immunology
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ. Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy. Methods & Clinical Development. 3: 15053. PMID 26858964 DOI: 10.1038/Mtm.2015.53  0.648
2016 Doerfler PA, Todd AG, Clément N, Falk DJ, Nayak S, Herzog RW, Byrne BJ. Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease. Human Gene Therapy. 27: 43-59. PMID 26603344 DOI: 10.1089/Hum.2015.103  0.668
2015 Doerfler PA, Nayak S, Herzog RW, Morel L, Byrne BJ. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clinical Immunology (Orlando, Fla.). 158: 140-7. PMID 25842186 DOI: 10.1016/J.Clim.2015.03.022  0.621
2015 Biswas M, Sarkar D, Kumar SR, Nayak S, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood. 125: 2937-47. PMID 25833958 DOI: 10.1182/Blood-2014-09-599266  0.639
2015 Biswas M, Sarkar D, Nayak S, Kumar SR, Rogers GL, Markusic DM, Liao G, Terhorst C, Herzog RW. 293. Optimal In Vivo Treg Induction and Suppression of Immune Responses By Synergistic Use of Rapamycin and FLT3 Ligand Molecular Therapy. 23: S118. DOI: 10.1016/S1525-0016(16)33902-8  0.679
2014 Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, Conlon T, Clément N, Erger K, Lavassani E, Green M, Doerfler P, Herzog R, Byrne B. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Molecular Therapy. Methods & Clinical Development. 1. PMID 25541616 DOI: 10.1038/Mtm.2014.33  0.651
2014 Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. Plos One. 9: e98336. PMID 24897114 DOI: 10.1371/Journal.Pone.0098336  0.63
2014 Elmallah MK, Falk DJ, Nayak S, Federico RA, Sandhu MS, Poirier A, Byrne BJ, Fuller DD. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 702-12. PMID 24336173 DOI: 10.1038/Mt.2013.282  0.399
2014 Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, Herzog RW, Byrne BJ. Antibody responses to varying doses of rhGAA in null mutation (n = 6) or P545L mutant mice (n = 5). Plos One. DOI: 10.1371/Journal.Pone.0098336.G003  0.537
2014 Doerfler PA, Kelley JS, Nayak S, Lawson LA, Byrne BJ. Pharmacological chaperones prevent the precipitation of rhGAA by anti-GAA antibodies during enzyme replacement therapy Molecular Genetics and Metabolism. 111. DOI: 10.1016/J.Ymgme.2013.12.073  0.387
2013 Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA, High KA, Herzog RW. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. Embo Molecular Medicine. 5: 1698-709. PMID 24106230 DOI: 10.1002/Emmm.201302859  0.716
2013 Elder ME, Nayak S, Collins SW, Lawson LA, Kelley JS, Herzog RW, Modica RF, Lew J, Lawrence RM, Byrne BJ. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. The Journal of Pediatrics. 163: 847-54.e1. PMID 23601496 DOI: 10.1016/J.Jpeds.2013.03.002  0.584
2012 Nayak S, Sivakumar R, Cao O, Daniell H, Byrne BJ, Herzog RW. Mapping the T helper cell response to acid α-glucosidase in Pompe mice. Molecular Genetics and Metabolism. 106: 189-95. PMID 22494547 DOI: 10.1016/J.Ymgme.2012.03.009  0.66
2012 Nayak S, Porvasnik S, Kelley J, Lee N, Byrne B. High Dose Rituximab Pretreatment in a New Human cd20-GAA−/− Mouse Model Causes Complete B-Cell Depletion and Reduction in Effector and Memory T-Cell Activation Molecular Genetics and Metabolism. 105: S48. DOI: 10.1016/J.Ymgme.2011.11.120  0.388
2011 Nayak S, Sarkar D, Perrin GQ, Moghimi B, Hoffman BE, Zhou S, Byrne BJ, Herzog RW. Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B. Frontiers in Microbiology. 2: 244. PMID 22279442 DOI: 10.3389/Fmicb.2011.00244  0.71
2011 Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Induction of tolerance to factor VIII by transient co-administration with rapamycin. Journal of Thrombosis and Haemostasis : Jth. 9: 1524-33. PMID 21585650 DOI: 10.1111/J.1538-7836.2011.04351.X  0.717
2011 Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ, Clement N, Cleaver BD, Cloutier DA, Porvasnik SL, Islam S, Elmallah MK, Martin A, et al. Pompe disease gene therapy. Human Molecular Genetics. 20: R61-8. PMID 21518733 DOI: 10.1093/Hmg/Ddr174  0.561
2011 Nayak S, Kelley J, Falk L, Lawson L, Harfe K, Collins S, Wasserfall C, Atkinson M, Elder M, Byrne B. Immune modulation in early onset Pompe disease Molecular Genetics and Metabolism. 102: S31-S32. DOI: 10.1016/J.Ymgme.2010.11.107  0.34
2010 Liao G, Nayak S, Regueiro JR, Berger SB, Detre C, Romero X, de Waal Malefyt R, Chatila TA, Herzog RW, Terhorst C. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells. International Immunology. 22: 259-70. PMID 20139172 DOI: 10.1093/Intimm/Dxq001  0.638
2010 Nayak S, Herzog RW. Progress and prospects: Immune responses to viral vectors Gene Therapy. 17: 295-304. PMID 19907498 DOI: 10.1038/Gt.2009.148  0.637
2010 Nayak S, Moghimi B, Herzog RW. Strategies to Prevent or Reverse Immune Responses Against Factor In Gene Replacement for Hemophilia B. Blood. 116: 3761-3761. DOI: 10.1182/Blood.V116.21.3761.3761  0.719
2010 Markusic D, Nayak S, Herzog RW. Humoral and Anaphylactic Responses to Factor IX In Murine Hemophilia B Are Genotype Dependent and Can Be Reversed by Hepatic Gene Transfer Blood. 116: 2202-2202. DOI: 10.1182/Blood.V116.21.2202.2202  0.674
2009 Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, Byrne BJ, Terhorst C, Herzog RW. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. Plos One. 4: e6376. PMID 19652717 DOI: 10.1371/Journal.Pone.0006376  0.632
2009 Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, Ertl HC, High KA, Herzog RW. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1733-42. PMID 19603001 DOI: 10.1038/Mt.2009.159  0.722
2009 Nayak S, Cao O, Hoffman BE, Cooper M, Zhou S, Atkinson MA, Herzog RW. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells Journal of Thrombosis and Haemostasis. 7: 1523-1532. PMID 19583824 DOI: 10.1111/J.1538-7836.2009.03548.X  0.682
2009 Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Human Gene Therapy. 20: 767-76. PMID 19309290 DOI: 10.1089/Hum.2008.161  0.662
2008 Nayak S, Hoffman B, Cooper M, Atkinson M, Cao O, Herzog RW. A Prophylactic Protocol for the Prevention of Inhibitor Formation in Gene Therapy for Hemophilia B by Shifting the Balance from An Effector to a Regulatory T Cell Response Blood. 112: 3531-3531. DOI: 10.1182/Blood.V112.11.3531.3531  0.644
2007 Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 110: 1132-40. PMID 17438084 DOI: 10.1182/Blood-2007-02-073304  0.642
2006 Cao O, Wang L, Nayak S, Herzog RW. Regulatory CD4+CD25+ T Cells Are Required for Tolerance Induction to Factor IX by In Vivo Gene Transfer. Blood. 108: 452-452. DOI: 10.1182/Blood.V108.11.452.452  0.626
Show low-probability matches.